Welcome to our dedicated page for Cosciens Biopharma SEC filings (Ticker: CSCI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The COSCIENS Biopharma Inc. (CSCI) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a foreign private issuer. COSCIENS files reports such as Form 20-F annual reports and Form 6-K current reports, which include financial statements, management’s discussion and analysis, and press releases on strategic initiatives, clinical programs and capital markets decisions.
Through these filings, investors can review how COSCIENS describes its business as a life sciences company focused on natural, plant-based active ingredients, cosmeceutical, nutraceutical and pharmaceutical products, and diagnostic assets like macimorelin (Macrilen; Ghryvelin) for adult growth hormone deficiency. The filings also discuss the company’s proprietary extraction technologies, its use of Pressurized Gas eXpanded (PGX) Technology, and the evolution of its portfolio following the merger of Aeterna Zentaris and Ceapro.
Key documents available or referenced via SEC filings include quarterly and interim financial statements, risk factor discussions, and detailed commentary on cost structure realignment, restructuring and zero-based budgeting initiatives. Filings also record important capital markets events, such as COSCIENS’ voluntary delisting from the Nasdaq Capital Market via Form 25, while retaining its Toronto Stock Exchange listing and seeking quotation for its shares in the U.S. over-the-counter market under the symbol CSCIF.
Stock Titan’s platform surfaces these filings alongside AI-powered summaries that explain complex sections, highlight changes from prior periods and point out items relevant to CSCI shareholders, such as discussions of Macrilen commercialization, PGX Technology scale-up and strategic program decisions. Users can quickly scan recent 6-K submissions, annual 20-F reports and other key documents to understand COSCIENS’ financial position, strategic direction and regulatory reporting history.
COSCIENS Biopharma Inc. removed 10,190,859 registered common shares and related purchase rights from its Form F-1 registration by filing Post-Effective Amendment No. 6.
The amendment states the company terminated the offering under Registration Statement File No. 333-248561 and, consistent with its undertakings, is terminating effectiveness and removing any unsold securities. The original registration covered shares issuable on exercise of certain unregistered warrants exercisable through February 5, 2026 and August 3, 2025.
COSCIENS Biopharma Inc. terminates the Form F-1 offering that had registered up to 14,457,831 units with a proposed aggregate offering price of up to $12,000,000.
This Post-Effective Amendment No. 6 deregisters and removes from registration any unsold registered Units, Pre-Funded Units, Common Warrants, Placement Agent Warrants and the underlying Shares as of the amendment's effectiveness.
COSCIENS Biopharma Inc. filed Post-Effective Amendment No. 1 to its Form F-1 to terminate the offering and deregister securities previously registered under Registration No. 333-277115.
The original Registration Statement registered the issuance of up to 633,583 common share purchase warrants and up to 633,583 Shares issuable upon exercise of those Warrants, of which 579,037 Warrants were issued to Shareholders and 54,546 Warrants were issued to Existing Warrant Holders. The amendment terminates the offering in the United States and removes from registration any and all securities remaining unsold as of the effective date of this Post-Effective Amendment.
COSCIENS Biopharma Inc. has filed Post-Effective Amendment No. 6 to its Form F-1 to terminate the offering and remove from registration any unsold securities under Registration Statement No. 333-239019. The original registration, declared effective June 16, 2020, had registered up to 6,177,174 common shares issuable upon exercise of certain warrants. This amendment, signed March 13, 2026, states the Company has terminated the offering and removes all securities remaining unsold as of effectiveness.
COSCIENS Biopharma Inc. has decided to stop funding its German subsidiaries, Aeterna Zentaris GmbH and Zentaris IVF GmbH. The Company expects these entities to enter a structured insolvency process and to surrender its rights to Macrilen, its main FDA and EMA approved pharmaceutical asset.
Management explains that Macrilen and the broader biopharmaceutical business have operated at a loss, and a failed Phase 3 DETECT trial for a pediatric indication in the U.S. undermined growth plans. COSCIENS plans to significantly cut ongoing operating expenses and focus on its plant-based active ingredients business, including avenanthramides and beta glucan used in skincare products.
COSCIENS Biopharma Inc. filed a report describing an upcoming special meeting of its security holders. The company, through its transfer agent Computershare, set March 3, 2026 as the record date for notice and voting, with the meeting scheduled for April 7, 2026 as a virtual event.
The filing also reiterates extensive forward-looking statement cautions, highlighting risks related to its patented technologies, nutraceutical and pharmaceutical product development, facility build-outs, liquidity and capital resources, and overall business strategy. Common shares are identified as the voting security for this special meeting.
COSCIENS Biopharma Inc. furnished a Form 6-K that includes its Q3 2025 interim financial materials and related certifications. The filing lists Exhibits 99.1–99.4, covering condensed interim consolidated financial statements for the third quarter of 2025, management’s discussion and analysis, and CEO/CFO certifications under National Instrument 52-109.
The exhibits are incorporated by reference into the company’s existing Form S-8 registration statements and are deemed part of those filings from the date this Form 6-K is furnished. The company also includes forward-looking statements and directs readers to risk factors in its most recent Annual Report on Form 20-F.